Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S L Goh

Showing results (51-60 of 59) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 59 results.
BMC Pulmonary Medicine|November 11, 2021
High intensity interval training versus moderate intensity continuous training for people with interstitial lung disease: protocol for a randomised controlled trialLeona M Dowman, Anthony K May, Catherine J Hill, et al.
Nature Communications|April 12, 2013
Titanium dioxide nanomaterials cause endothelial cell leakiness by disrupting the homophilic interaction of VE-cadherinM I Setyawati, C Y Tay, S L Chia, et al.
American Journal of Respiratory and Critical Care Medicine|March 29, 2008
Interstitial lung disease in systemic sclerosis: a simple staging systemNicole S L Goh, Sujal R Desai, Srihari Veeraraghavan, et al.
The Journal of Rheumatology|February 5, 2013
Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosisAngelo De Lauretis, Piersante Sestini, Panagiotis Pantelidis, et al.
BMJ Open|December 15, 2020
Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX trial): a randomised controlled trialAnne E Holland, Tamera Corte, Daniel C Chambers, et al.
Respirology (Carlton, Vic.)|January 11, 2024
Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revisionJohn A Mackintosh, Gregory Keir, Lauren K Troy, et al.
Arthritis and Rheumatism|November 30, 2006
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in sclerodermaRachel K Hoyles, Ross W Ellis, Jessica Wellsbury, et al.
Respiratory Research|December 5, 2025
A randomised clinical trial of a digital self-management package for people with interstitial lung disease: the REBUILD-SM protocolCarly Barton, Mariana Hoffman, Narelle S Cox, et al.
Respirology (Carlton, Vic.)|November 24, 2020
Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New ZealandAdelle S Jee, Robert Sheehy, Peter Hopkins, et al.
Pageof 6

Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
BMC Pulmonary Medicine|November 11, 2021
High intensity interval training versus moderate intensity continuous training for people with interstitial lung disease: protocol for a randomised controlled trialLeona M Dowman, Anthony K May, Catherine J Hill, et al.
Nature Communications|April 12, 2013
Titanium dioxide nanomaterials cause endothelial cell leakiness by disrupting the homophilic interaction of VE-cadherinM I Setyawati, C Y Tay, S L Chia, et al.
American Journal of Respiratory and Critical Care Medicine|March 29, 2008
Interstitial lung disease in systemic sclerosis: a simple staging systemNicole S L Goh, Sujal R Desai, Srihari Veeraraghavan, et al.
The Journal of Rheumatology|February 5, 2013
Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosisAngelo De Lauretis, Piersante Sestini, Panagiotis Pantelidis, et al.
BMJ Open|December 15, 2020
Ambulatory oxygen for treatment of exertional hypoxaemia in pulmonary fibrosis (PFOX trial): a randomised controlled trialAnne E Holland, Tamera Corte, Daniel C Chambers, et al.
Respirology (Carlton, Vic.)|January 11, 2024
Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revisionJohn A Mackintosh, Gregory Keir, Lauren K Troy, et al.
Arthritis and Rheumatism|November 30, 2006
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in sclerodermaRachel K Hoyles, Ross W Ellis, Jessica Wellsbury, et al.
Respiratory Research|December 5, 2025
A randomised clinical trial of a digital self-management package for people with interstitial lung disease: the REBUILD-SM protocolCarly Barton, Mariana Hoffman, Narelle S Cox, et al.
Respirology (Carlton, Vic.)|November 24, 2020
Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New ZealandAdelle S Jee, Robert Sheehy, Peter Hopkins, et al.
Pageof 6